Brazil’s Private-Health Duopoly Splits: Rede D’Or Surges as Hapvida’s Verticalization Stumbles

Brazil’s two largest private-health groups made the same bet — fuse an insurer to a hospital empire and own the entire chain. In 2026 that bet is paying off spectacularly for one of them and unravelling for the other.

Sources: Brazil health-plan regulator beneficiary data via ADVFN (advfn.com); Q2 2026 results via Futuro da Saúde (futurodasaude.com.br) and InfoMoney (infomoney.com.br).

The logic of verticalization is seductive. If an insurer owns the hospitals, clinics and laboratories where its members are treated, it can internalize the single largest line on its income statement — the medical-cost ratio — and steer patients toward its own assets. Cheaper premiums, captive care, fatter margins. Both Hapvida and Rede D’Or São Luiz built their strategies on that premise, each pairing a hospital network with a large health insurer: Hapvida through its 2022 merger with NotreDame Intermédica, Rede D’Or through its acquisition of the insurer SulAmérica.

By the second quarter of 2026, the two companies were living in different economies. Rede D’Or reported net revenue of roughly R$14.9 billion, net income of about R$1.3 billion — up 8.5% — and EBITDA up 18.2%, with its SulAmérica insurance arm growing operating earnings by more than half. Hapvida, by contrast, watched adjusted net profit collapse almost 96% to R$12.5 million on revenue of R$7.97 billion, as its loss ratio — the share of premiums paid out in claims — climbed to 75.2% and the company posted an accounting loss for the period. Its market value fell to the lowest level since it went public in 2018.

The divergence matters because it is a real-time stress test of a model that now dominates Brazilian healthcare. Rede D’Or operates 79 hospitals; Hapvida runs 88 of its own, alongside hundreds of clinics and diagnostic centers. When two groups of that scale own the beds, independent hospitals and the listed diagnostic chains — Dasa, Grupo Fleury, Oncoclínicas — lose bargaining power, because the insurer-hospital combinations can direct patient flow to assets they already own and squeeze the fees paid to accredited outsiders. The strain is already visible elsewhere in the sector: Oncoclínicas, the country’s largest oncology network, filed in 2026 for an extrajudicial restructuring of R$5.1 billion in debt.

Hapvida’s response reveals the harder edge of the consolidation thesis. Rather than serve members who cost more than they pay, the company disclosed a review of roughly 947,000 “deficit” beneficiaries — contracts it intends to reprice or shed. In the language of managed care that is portfolio hygiene; to a regulator it looks like a large insurer pruning its costliest and least-profitable members from a market of 53.2 million people. That is precisely the kind of behavior the Agência Nacional de Saúde Suplementar (ANS), Brazil’s private-health regulator, exists to police, and it lands as concentration, tariff adjustments and court-ordered coverage — judicialization — are already under scrutiny.

Verticalization was sold as a way to bend the cost curve. Hapvida’s 2026 shows the curve can bend back — and that owning the whole chain is only an advantage if you can run it.

None of this proves that verticalization has failed. Rede D’Or’s strong year is the counter-evidence: the same structural bet, executed well, is compounding. Hapvida’s troubles may be a problem of integration and execution rather than of strategy, and its member losses are, on the company’s own account, a deliberate repair job that could look far better by 2027. Medical inflation and rising litigation are squeezing every operator, consolidated or not, and no antitrust ruling or tariff crackdown has yet materialized. But the episode has punctured the assumption that scale plus ownership equals durable margin — and it has handed the regulator a live case study in what happens when a dominant player decides that the cheapest patient is the one it no longer covers.